HighCALS intervention development study

  • Research type

    Research Study

  • Full title

    HighCALS intervention development: A qualitative study to develop, refine and assess the acceptability of a complex intervention to increase nutritional intake in people with Amyotrophic Lateral Sclerosis.

  • IRAS ID

    250732

  • Contact name

    Christopher McDermott

  • Contact email

    c.j.mcdermott@sheffield.ac.uk

  • Sponsor organisation

    Sheffield Teaching Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 6 months, 30 days

  • Research summary

    Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease, is a devastating and progressive condition. It affects the nervous system and eventually causes paralysis and death. Research suggests that for those people with ALS that are able to maintain their body weight, there is an increase in survival time.

    However, due to the impact that the disease has on swallowing, alongside an increase in energy requirements, it is often difficult for people to eat and drink sufficient meaning that weight loss is inevitable. There is also a lack of guidance around how best we can support people to meet their nutritional needs.

    We are undertaking a large programme of research to develop and test a nutritional support framework for people with ALS. This application is for the second phase of this work, which we are calling the ‘intervention development study’.

    This study will involve two phases – in phase 1, we will undertake interviews with people with ALS and their carers, and focus groups with ALS healthcare professionals, to find out about their views on what promotes or prevents best nutritional practice in ALS.

    In phase 2, we will use the information gathered in phase 1, alongside that from others parts of our programme, including surveys and reviews of the literature, to help us develop and test a nutritional support package for people with ALS. We will interview patients, carers and healthcare professionals to get their opinions on what we have developed, and as we further refine this, they will be given the package to test for themselves.

    We will use all of this information to finalise the support package, which we will then test in a randomised controlled trial in the next phase of our work.

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    18/NW/0638

  • Date of REC Opinion

    27 Sep 2018

  • REC opinion

    Favourable Opinion